临床儿科杂志 ›› 2024, Vol. 42 ›› Issue (11): 942-947.doi: 10.12372/jcp.2024.23e1051

• 论著 • 上一篇    下一篇

5例17p13.3微缺失综合征临床特征分析及疗效评价

汪莉波1,2, 张倩文1,2, 姚如恩2,3, 唐怡珺1,2, 高诗阳1,2, 李智颖1,2, 胡斐涵1,2, 李辛1,2, 娄丹4(), 王秀敏1,2()   

  1. 1.上海交通大学医学院附属上海儿童医学中心内分泌代谢科/医学遗传科(上海 200127)
    2.上海交通大学医学院附属上海儿童医学中心 上海市罕见病临床研究中心(上海 200127)
    3.上海交通大学医学院附属上海儿童医学中心遗传分子诊断科(上海 200127)
    4.河南科技大学第一附属医院儿科(河南 471003)
  • 收稿日期:2023-10-26 出版日期:2024-11-15 发布日期:2024-11-08
  • 通讯作者: 娄丹,王秀敏 E-mail:loudan69@163.com;wangxiumin1019@126.com
  • 基金资助:
    上海市儿童罕见病临床研究中心(20MC1920400);上海市卫生健康委员会临床研究专项(20204Y0348);浦东新区卫健委联合攻关项目(PW2021D-13);上海交通大学医学院儿科学院单病种研究中心项目(ELYZX202107);中央高校基本科研业务费专项资金资助(YG2023QNA35);国家重点研发计划(2022YFC2703102)

Clinical characterization of five children with 17p13.3 microdeletion syndrome and evaluation of their efficacy

WANG Libo1,2, ZHANG Qianwen1,2, YAO Ruen2,3, TANG Yijun1,2, GAO Shiyang1,2, LI Zhiying1,2, HU Feihan1,2, LI Xin1,2, LOU Dan4(), WANG Xiumin1,2()   

  1. 1. Department of Endocrinology and Metabolism, Department of Medical Genetics, Shanghai Children′s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2. Shanghai Rare Disease Clinical Research Center, Shanghai Children′s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    3. Department of Genetic and Molecular Diagnosis, Shanghai Children′s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    4. Department of Pediatrics, The First Affiliated Hospital of Henan University of Science and Technology, Henan 471003, China
  • Received:2023-10-26 Online:2024-11-15 Published:2024-11-08
  • Contact: LOU Dan,WANG Xiumin E-mail:loudan69@163.com;wangxiumin1019@126.com

摘要:

目的 探讨17p13.3微缺失综合征的临床表型、拷贝数变异、治疗及预后。方法 回顾性分析5例17p13.3微缺失综合征患儿临床资料、全外显子组测序结果以及治疗效果。结果 5例患儿均表现为身材矮小,例3~5合并有心血管异常。全外显子组测序提示所有的患儿均存在17p13.3染色体片段缺失,缺失大小为433~1 536 kb,主要包括YWHAECRK基因,但不包括PAFAH1B1基因。在排除了生长激素禁忌证后,4例接受了重组人生长激素治疗。矮小症患儿的身高在应用重组人生长激素治疗后初期得到改善,但后期治疗效果欠佳。2例满足手术指征而接受外科手术以纠正先天性心脏畸形。结论 17p13.3染色体片段缺失可导致17p13.3微缺失综合征,通过全外显子组测序,可以提高对于存在先天性心脏畸形和/或矮小症的儿童的诊断率,及时采取心血管及身高方面的治疗有助于改善患儿预后。

关键词: 17p13.3微缺失, 全外显子组测序, 身材矮小, 先天性心脏病

Abstract:

Objective The aim of this study was to explore the clinical manifestations, genetic copy number variations, therapeutic responses, and prognostic factors associated with 17p13.3 microdeletion syndrome in pediatric patients. Methods A retrospective analysis was conducted on the clinical profiles, whole exome sequencing data, and therapeutic outcomes of five pediatric cases diagnosed with 17p13.3 microdeletion syndrome. Results All 5 patients presented with short stature, and those in cases 3 to 5 also exhibited cardiovascular abnormalities. Whole exome sequencing identified a 433kb to 1536kb deletion within the 17p13.3 chromosomal region, predominantly affecting the YWHAE and CRK genes without implicating the PAFAH1B1 gene. Following the exclusion of contraindications, cases 1 to 4 were administered recombinant human growth hormone (rhGH). While the initial response to rhGH treatment was promising with improvements in height, the long-term efficacy was suboptimal. Cases 4 and 5 underwent surgical correction for congenital heart disease as indicated. Conclusion Deletion of 17p13.3 can result in 17p13.3 microdeletion syndrome. Whole exome sequencing is instrumental in the prompt diagnosis of children exhibiting signs of congenital heart disease and/or short stature. Timely and appropriate interventions for cardiovascular and height-related issues are essential for improving the overall prognosis of affected children.

Key words: 17p13.3 microdeletion, whole exome sequencing, short stature, congenital heart disease